semaglutide body weight loss Change With Who Qualifies for Semaglutide GLP-1

Mosquera-Sulbaran et al., 2021)

Neuronal injury, gliosis, and glial proliferation in two models of temporal lobe epilepsy

The closest performing GLP-1 medicine in terms of average weight loss is Novo Nordisks CagriSema, an Amylin/GLP-1 dual agonist, which had an average weight loss of 22.7% after 68 weeks in Phase 3 trials

Dissimilar to proven weight loss injections such as Mounjaro and Wegovy, which contain actual GLP-1 medication, most patches rely on herbal ingredients with limited effectiveness for appetite regulation

This mechanism reduces the likelihood of overeating, aiding in sustainable weight management